to differentiate into an antibody-secreting cell or return to the dark zone? In addition to providing a platform for addressing these questions, the powerful application of photoactivatable-GFP in this study should spur broader use of this technology to relate cell location with gene expression and cell fate.
Perception of pain involves both the peripheral and central nervous systems. Starting with a wholegenome RNA interference screen in Drosophila, Neely et al. (2010) identify a mammalian gene that is required not only for efficient transfer of pain signals between brain centers, but also for the suppression of inappropriate signaling between other sensory systems.
Even though humanity's attempts to control pain can be traced back through the millennia, much of our current arsenal of therapies still has its roots in folk remedies. Originally derived from natural plant products such as willow bark and poppies, these medicines have been the mainstay of chronic pain control for many years. Unfortunately, even modern therapies for chronic pain are too often ineffective, leaving untold numbers of individuals suffering worldwide. As we move into the postgenomic era, hopes have been raised that the problem of pain will be solved, largely by getting to grips with the underlying genetic, molecular, and cellular mechanisms involved in nociception. It is also expected that interindividual variability in pain experience, a major issue confounding effective treatment, will be accounted for in some part by variations in a definable subset of genes.
The report by Neely et al. (2010) in this issue of Cell represents a major advance in the search for the genes and mechanisms of pain and variability in its perception. In an impressively multifaceted study that extends from fruit flies to mice and ultimately to humans, the authors have uncovered a new molecular player, a2d3, in pain. Along the way, they also made some highly unexpected observations indicating that a2d3 is not only involved in pain, but also plays a role in the poorly understood mechanisms that separate one form of sensory information from another.
The fruit fly provides an ideal model for unraveling genetic aspects of human disease, with advantages including a short generation time and the capacity to analyze extremely large numbers of animals in a high-throughput manner. Genome-wide RNA interference (RNAi) screens are a powerful investigative tool given the fly's relatively small (15,000 genes) but extremely well-annotated genome and sufficient homology with the human genome to permit the identification of conserved pathways in flies and humans.
In a Herculean undertaking, Neely et al. take advantage of the Vienna global Drosophila RNAi library (Dietzl et al., 2007) to individually knock down almost every gene in the fly genome, specifically in neural tissues. Each line was then painstakingly tested using a behavioral assay to measure sensitivity to noxious heat. In total, 580 genes are identified that potentially regulate thermal nociception and possibly basic neuronal function. One of the genes identified is straightjacket, which is one of several a2d genes that encode calcium channel subunits. The mammalian homolog of straightjacket is CACNAD2D3, which encodes the a2d3 subunit. Of interest, a close relative of this protein, a2d1, is the molecular target for the analgesics gabapentin and pregabalin (Field et al., 2006) . To further investigate the function of a2d3, the authors generated a knockout mouse.
Intriguingly, its expression in the mouse is entirely restricted to the brain, being completely absent from the spinal cord and dorsal root ganglia. This suggests that, unlike the function of Straightjacket in flies, mammalian a2d3 likely mediates the last leg of the nociceptive relay, the transmission of the signal from the thalamus up to the highest level, the cortex.
To test the relevance of their findings in humans, Neely et al. identify and screen four single-nucleotide polymorphisms (SNPs) in the human CACNA2D3 gene. One of these, rs6777055, is significantly associated with reduced thermal sensitivity. In these experiments, the volunteers are given a series of short pulses of painful heat. Although the temperature of the pulses remains the same, most people tend to perceive the stimulus as becoming progressively more painful. In a small number of subjects, however, this does not occur, and it is these individuals that are found to express the rs6777055 minor allele of the CACNA2D3 gene.
Surprising similarities emerge between the a2d3 knockout mouse and humans with SNPs that interfere with a2d3 function. For both, it appears that acute pain sensitivity is reduced (although spinal reflex-mediated events such as tail flick remain normal, in line with the absence of a2d3 expression in peripheral and spinal sensory circuitry in the mouse). Furthermore, both thermal hypersensitivity following inflammation in mice and perception of chronic back pain in humans appear to involve a2d3; patients expressing the rs6777055 SNP report reduced pain 1 year after corrective surgery compared to non-SNP patients.
In addition to the remarkable insight into pain processing that these studies reveal, a fascinating and unexpected phenomenon emerges from their studies using functional magnetic resonance imaging (fMRI) of the a2d3-deficient mice. Noxious thermal stimulation normally activates a characteristic set of brain structures associated with pain perception. Known as the pain matrix, this center includes the thalamus and somatosensory cortex. In the a2d3 mutant mouse, activation of the pain matrix is markedly diminished, with the fMRI signal seemingly unable to spread from the thalamus to higher cortical regions. Therefore, it appears that, in mammals, a2d3 is necessary not for the detection of noxious heat but for the transmission of thermal nociceptive signals to higher areas of the central nervous system, in particular those associated with the processing of pain signals.
However, this is not the only finding of the fMRI study. When looking at total activation in the brain, the authors find no difference between control and a2d3-deficient mice. This at first seems counterintuitive, given the large reduction in fMRI signal from thalamocortical projections in the mutant mouse. Upon closer investigation, it becomes evident that other entirely unrelated brain regions are instead being activated, including visual, auditory, and olfactory regions (Figure 1 ). Even more remarkably, when another sensory modality, tactile stimulation of the vibrissae, is tested, not only does the MRI signal in the primary cortical area (the barrel fields of the somatosensory cortex) remain unchanged in mutant compared to wild-type mice, but cross-activation to other sensory brain regions is also observed.
It therefore appears that mice lacking a2d3 develop a form of synesthesia, a condition whereby stimulation of one sensory pathway elicits perception in one or more other sensory modalities. Although transmission of thermal nociception is diminished, other sensory systems tested, such as touch, remain unaffected.
The study by Neely et al. offers a compelling insight into nociceptive transmission in higher areas of the central nervous system. In doing so, it also raises many questions for future investigation. On a molecular level, a2d3 is known to regulate calcium channel expression and its targeting to presynaptic sites (Dolphin, 2009) . A recent report suggests that a2d3 can be GPI anchored to the membrane and that this modification is necessary for a2d3-mediated enhancement of calcium currents (Davies et al., 2010; Bauer et al., 2010) . Evidence is also now emerging that, in Drosophila, a2d3 is required for synaptic morphogenesis (Kurshan et al., 2009) . Of interest, however, this function appears to be independent of its role in regulating voltagegated calcium channels. In light of this multifunctionality, the question arises as to what exactly is deficient in the a2d3-deficient mice. In particular, the synaptic consequences of eliminating a2d3 throughout mouse development remain unknown.
Given the close relationship between a2d3 and a2d1, it would also be of great interest to test what happens to a2d3 expression after peripheral nerve injury, as a2d1 is upregulated in the somatosensory system after nerve injury, concurrent with the onset of behavioral pain hypersensitivity. Furthermore, although the human studies presented indicate that In the mouse brain, nociceptive signals are relayed from the thalamus to the somatosensory and motor regions of the cortex. Visualized by functional magnetic resonance imaging (fMRI), mice lacking the gene encoding a2d3 display a significant reduction in activation of these regions, consistent with reduced perception of a painful thermal stimulus. Surprisingly, however, other regions of the cortex, including those involved in olfaction, vision, and hearing, are activated by the same stimulus. chronic pain states may indeed be mediated by the action of a2d3, it remains to be seen whether this can be modeled in mice. Finally, the cross-sensory activation in a2d3-deficient mice raises the question as to whether synesthesia in humans is in any way related to a2d3 polymorphisms.
Despite considerable research and major mechanistic breakthroughs in recent years, pain remains the most common cause of disability and impaired quality of life and, as such, represents an enormous socioeconomic problem. The identification of a2d3 as a player in the mechanisms of pain and a molecule accounting for a portion of interindividual pain variability opens up new possibilities for rationally designed and individualized pain therapies. The biggest challenge now is to find safe and effective ways to use this discovery to truly put a straightjacket on pain.
